proteon manager 3.1.0 Search Results


bio rad proteon manager software  (Bio-Rad)
96
Bio-Rad bio rad proteon manager software
Bio Rad Proteon Manager Software, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/ProteOn+Manager+Software/pmc05673489-1069-8-8
Average 96 stars, based on 1 article reviews
bio rad proteon manager software - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
proteon manager version 3 1 0 6  (Bio-Rad)
93
Bio-Rad proteon manager version 3 1 0 6
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Proteon Manager Version 3 1 0 6, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/ProteOn+HTG+Sensor+Chip/pmc07233522-125-9-13
Average 93 stars, based on 1 article reviews
proteon manager version 3 1 0 6 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
proteus mirabilis hauser  (ATCC)
96
ATCC proteus mirabilis hauser
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Proteus Mirabilis Hauser, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/Proteus+mirabilis+Hauser/custom%4025933%4031022215
Average 96 stars, based on 1 article reviews
proteus mirabilis hauser - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
enterococcus faecalis schleifer and kilpper-balz  (ATCC)
99
ATCC enterococcus faecalis schleifer and kilpper-balz
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Enterococcus Faecalis Schleifer And Kilpper Balz, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/Enterococcus+faecalis+Schleifer+and+Kilpper-Balz/custom%4051299%4031022215
Average 99 stars, based on 1 article reviews
enterococcus faecalis schleifer and kilpper-balz - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
candida albicans berkhout  (ATCC)
99
ATCC candida albicans berkhout
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Candida Albicans Berkhout, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/Candida+albicans+Berkhout/custom%4010231%4031022215
Average 99 stars, based on 1 article reviews
candida albicans berkhout - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
escherichia coli castellani and chalmers  (ATCC)
99
ATCC escherichia coli castellani and chalmers
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Escherichia Coli Castellani And Chalmers, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/Escherichia+coli+Castellani+and+Chalmers/custom%4025922%4031022215
Average 99 stars, based on 1 article reviews
escherichia coli castellani and chalmers - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
gamunex2 immune globulin intravenous (human), 10% caprylate/ chromatography purified  (Talecris Biotherapeutics)
90
Talecris Biotherapeutics gamunex2 immune globulin intravenous (human), 10% caprylate/ chromatography purified
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Gamunex2 Immune Globulin Intravenous (Human), 10% Caprylate/ Chromatography Purified, supplied by Talecris Biotherapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/gamunex2+immune+globulin+intravenous++human+++10++caprylate++chromatography+purified/pm17407395-44-8-14
Average 90 stars, based on 1 article reviews
gamunex2 immune globulin intravenous (human), 10% caprylate/ chromatography purified - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant dna pmscv cre puro ires gfp addgene plasmid  (Addgene inc)
93
Addgene inc recombinant dna pmscv cre puro ires gfp addgene plasmid
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Recombinant Dna Pmscv Cre Puro Ires Gfp Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/MSCV-PIG-Cre+(Plasmid+%2350935)/pm33186519-454-98-101
Average 93 stars, based on 1 article reviews
recombinant dna pmscv cre puro ires gfp addgene plasmid - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
auy922  (Rexin Pharmaceuticals)
90
Rexin Pharmaceuticals auy922
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Auy922, supplied by Rexin Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/auy922/10__1159_slash_000375281-88-67-90
Average 90 stars, based on 1 article reviews
auy922 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ras/rap gtpase-activating protein  (SynGap Research Fund Inc)
90
SynGap Research Fund Inc ras/rap gtpase-activating protein
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Ras/Rap Gtpase Activating Protein, supplied by SynGap Research Fund Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/ras+rap+gtpase+activating+protein/pmc06301012-341-344-345
Average 90 stars, based on 1 article reviews
ras/rap gtpase-activating protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
trc105  (Tracon Inc)
90
Tracon Inc trc105
Patient Demographics and Clinical Characteristics
Trc105, supplied by Tracon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon+manager+3%2E1%2E0/trc105/pmc06599519-108-203-204
Average 90 stars, based on 1 article reviews
trc105 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) ProteOn array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.

Journal: Cancer immunology research

Article Title: Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA

doi: 10.1158/2326-6066.CIR-19-0023

Figure Lengend Snippet: (A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) ProteOn array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.

Article Snippet: For the assay, a HTG sensor chip (#1765031) and ProteOn Manager Version 3.1.0.6 (Bio-Rad Laboratories) were employed.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Recombinant, Negative Control, Control, Western Blot, Concentration Assay, Inhibition, Incubation, Comparison

Patient Demographics and Clinical Characteristics

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Article Title: Prospective Study Evaluating Na 18 F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer

doi: 10.2967/jnumed.115.166512

Figure Lengend Snippet: Patient Demographics and Clinical Characteristics

Article Snippet: Patients receiving treatment were assessed for response using the criteria of the Prostate Cancer Working Group 2 ( 14 ); Na 18 F PET/CT scans did not guide clinical decisions. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Known bone metastases at enrollment Characteristic Negative (n = 30) Positive (n = 30) Age (y) Median 65 64.5 Range 43–79 44–79 Baseline PSA (ng/mL) Median 10.97 9.93 Range 0.01–190 0.1–593 Gleason score 4 1 (3%) 0 6 4 (13%) 3 (10%) 7 7 (23%) 10 (33%) 8 8 (27%) 5 (17%) 9 9 (30%) 11 (37%) 10 0 1 (3%) On treatment at NIH Yes 6 (20%) 11 (37%) No 24 (80%) 19 (63%) Managed at NIH multidisciplinary clinic Yes 10(33%) 2 (7%) No 20 (66%) 28 (93%) Primary therapy Radical prostatectomy 14(47%) 13(43%) External-beam radiation 8 (26%) 7 (23%) Brachytherapy 2 (7%) 0 Castration status Sensitive 21 (70%) 13(43%) Resistant 9 (30%) 17 (57%) Therapy while on study GnRH agonist/antagonist (leuprorelin/degarelix) 28 26 Antiandrogen (bicalutamide, nilutamide) 14 13 Ketoconazole 1 4 Enzalutamide 0 1 Abiraterone 0 1 Docetaxel, bevacizumab, lenalidomide, prednisone 0 10 Taxane 0 2 Bisphosphonate (zoledronic acid/dasatinib) 3 6 Sipuleucel-T 0 3 Vaccine study (TARP, Prostvac [Bavarian Nordic]) 3 4 TRC105 (TRACON Pharmaceuticals) 1 1 Radiation 4 4 Open in a separate window NIH = National Institutes of Health; GnRH = gonadotropin-releasing hormone; TARP, T-cell receptor γ alternate reading frame protein.

Techniques: